IMO-2055: Additional Phase Ib data

Additional data from an open-label, dose-escalation, U.S. Phase Ib trial in 33 evaluable patients with advanced NSCLC who failed >=1 prior course of chemotherapy showed that subcutaneous IMO-2055 plus Tarceva erlotinib and Avastin bevacizumab led to a disease control rate (DCR) of 79%. Median PFS and OS were 5.6 and 16 months, respectively. IMO-2055 was well tolerated with diarrhea, nausea, fatigue and rash reported as the most common adverse events. Additionally, 0.32 mg/kg was identified as the recommended Phase II dose of the compound. Patients received 0.08, 0.16, 0.32 or 0.48 mg/kg IMO-2055 on days 1, 8 and 15 of a 3-week cycle plus Tarceva and Avastin. Idera previously reported interim data from 13 evaluable patients (see BioCentury, Oct. 5, 2009). ...